The expression BIRC6 gene in patients with chronic lymphocytic leukemia – a preliminary study

• Authors: Piotr Chomik , Paulina Gil-Kulik , Malgorzata Filas , Agnieszka Wojcieszek , Mateusz Wilinski , Jolanta Karwat , Lidia Kotula , Alicja Niedojadlo , Marcin Czop , Anna Bogucka-Kocka , Maria Cioch , Ryszard Pluta , Janusz Kocki
• Languages of publication: EN

Abstracts

EN

The BIRC6 gene encodes the Bruce (Apollon) protein. This belongs to the III class of Inhibitors of the Apoptosis Protein (IAP) and demonstrates anti-apoptotic activity (binding, inhibiting and degrading the caspases). Moreover, the Bruce protein shows multilevel activities and additional functions. The Bruce protein is involved in the maintenance of cell viability, and it is also suggested that it plays an important role in cell proliferation and diversification. Many researchers have noticed elevated BIRC6 gene expression in cell lines of brain cancer and ovarian carcinoma, leukemia, breast cancer and even in colorectal cancer tissues. Resistance to chemotherapy-inducted apoptosis in cancers characterized by BIRC6 gene over-expression was also reported. The aim of the study was to assess the BIRC6 gene expression in peripheral blood lymphocytes of patients diagnosed with chronic lymphocytic leukemia.

Keywords

EN

apoptosis; BIRC6 gene; Apollon; Bruce; CLL; chronic lymphocytic leukemia

• Publisher: De Gruyter Open
• Journal: Current Issues in Pharmacy and Medical Sciences
• Year: 2014
• Volume: 27
• Issue: 3
• Pages: 179-182

Dates

published

1 - 9 - 2014

received

19 - 9 - 2014

online

3 - 3 - 2015

accepted

7 - 11 - 2014

Contributors

author

Piotr Chomik

• Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska, 20-080 Lublin, Poland

author

Paulina Gil-Kulik

• Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska, 20-080 Lublin, Poland

author

Malgorzata Filas

• Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska, 20-080 Lublin, Poland

author

Agnieszka Wojcieszek

• Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska, 20-080 Lublin, Poland

author

Mateusz Wilinski

• Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska, 20-080 Lublin, Poland

author

Jolanta Karwat

• Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska, 20-080 Lublin, Poland

author

Lidia Kotula

• Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska, 20-080 Lublin, Poland

author

Alicja Niedojadlo

• Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska, 20-080 Lublin, Poland

author

Marcin Czop

• Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska, 20-080 Lublin, Poland

author

Anna Bogucka-Kocka

• Department of Pharmaceutical Botany, Medical University of Lublin, Poland

author

Maria Cioch

• Department of Haematology and Bone Marrow Transplantation, Medical University of Lublin, Poland

author

Ryszard Pluta

• Laboratory of Ischemic and Neurodegenerative Brain Research, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

author

Janusz Kocki

• Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska, 20-080 Lublin, Poland

References

• 1. Abe S. et al.: Bone marrow cells of mieloblastic syndromes exhibit significant expression of apollon, livin and ILP-2 with reduction after transformation to overt leukemia. Leukaemia Research 2005; 29: 1095-1096.[Crossref]
• 2. Bartke T. et al.:Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligasz. Md Cell 2004; 14: 801-811.[Crossref]
• 3. Bianchini M. et al.: Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol. 2006; 29: 83-94.
• 4. Bielak-Żmijewska A.: Mechanizmy oporności komórek nowotworowych na apoptozę. Problemy Nauk Biologicznych. Kosmos 2003; 52: 157-171.
• 5. Chen Z. et al.: A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun. 1999; 264: 847-854.
• 6. Deveraux Q.L., Reed J.C.: IAP family proteins suppressor of apoptosis. Genes Dev. 1999; 13: 239-252.[Crossref]
• 7. Ghavami S. et al.: Apoptosis and cancer: mutations within caspase. J Med Genet 2009; 46: 497-510.[WoS][Crossref]
• 8. Giannopoulos K.: Biologia i rokowanie w przewlekłej białaczce limfocytowej. Acta Haematologica Polonica 2010; 3: 433-440.
• 9. Grzybowska-Izydorczyk O., Smolewski P.: Białka inhibitorowe apoptozy z rodziny inhibitorów apoptozy (IAP) i ich antagoniści: rola biologiczna oraz potencjalne znaczenie w karcinogenezie i celowanej terapii przeciwnowotworowej. Acta Haematologica Polonica 2009; 40: 593-612.
• 10. Grzybowska-Izydorczyk O., Smolewski P.: Rola białek z rodziny inhibitora apoptozy (IAP) w chorobach rozrostowych układu krwiotwórczego. Postępy Hig Med. Dosw. 2008; 62: 55-63.
• 11. Guo J. et al.: A preliminary study on the implication of Apaf-1 promoter methylation and the expression of apoptosis inhibitor protein Apollon in adult acute leukaemia. Zhonghua Xue Ye Xue Za Zhi. 2010; 31: 736-739.
• 12. Ismail EA. Et al.: BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis. Eur J Haematol. 2012; 88:118-27. [53][WoS][Crossref]
• 13. Kaczmarek-Borowska B., Zmorzyński Sz., Filip A.: Biologiczna rola surwiwiny. Współczesna onkologia 2008; 10: 437-440.
• 14. Korzeniowska-Dyl I.: Kaspazy - struktura i funkcja. Pol. Merk. Lek. 2007; 138: 403-407.
• 15. Krawczyk-Kuliś M et al.: Nowe markery prognostyczne przewlekłej białaczki limfocytowej badane metodą immunofenotypizacji. Acta Haematologica Polonica 2012; 3: 271-276.[Crossref]
• 16. Lewandowski K, Matuszak M.: Czynniki prognostyczne w przewlekłej białaczce limfatycznej B-komórkowej. Współczesna Onkologia, 2003; 7:470-475.
• 17. Lopergolo A. et al.: Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. Journal List 2009; 100: 739-746.
• 18. Lotz K., Pyrowolakis G., Jentsch S.: BRUCE, a gigant E2/E3 ubiquitin ligase and inhibitor of apoptosis protein of the trans - Golgi network, is required for normal placenta development and mouse survival. Mol Cell Biol. 2004; 24: 9339-9350. [Crossref]
• 19. Malinowska I.: Rola apoptozy w patogenezie i leczeniu nowotwór układu hematopoetycznego. Postępy Hig Med. Dosw. 2004; 58: 548-559.
• 20. Mitrus I., Missot-Kolka E., Szala S.: Geny proapoptotyczne w terapii genowej nowotworów. Współczesna onkologia 2001; 5: 242-249.
• 21. Pohl C., Jentsch S.: Final stages of cytokinesis and mid-body ring formation are controlled by BRUCE. Cell 2008; 132: 832-845.[Crossref]
• 22. Qiu X.B. et al.: Nrdpl-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis. EMBO J. 2004; 23: 800-810.[Crossref]
• 23. Rumble J.M., Duckett C.S.: Diverse function within the IAP family. Journal of Cell Science 2008; 121: 3505-3507.[Crossref]
• 24. Rupniewska Z., Koczkodaj D., Wąsik-Szczepanek E.: BRUCE/ Apollon i jego rola w rodzinie białek hamujących apoptozę. Acta Haematologica Polonica 2006; 37: 329-337.
• 25. Salilew-Wondim D et al.:. Depletion of BIRC6 leads to retarded bovine early embryonic development and blastocyst formation in vitro. Reprod Fertil Dev. 2010; 22: 564-79.[Crossref]
• 26. Stańczyk M., Majsterek I.: Apoptoza - cel ukierunkowanej terapii przeciwnowotworowej. Postępy Biologii Komórki, 2008; 35: 467-484.
• 27. Sung K.W. et al.: Over-expression of Apollon, an antiapoptotic protein is Associated with Poor Prognosis in Childhood De novo Acute Myeloid Leukemia. Clin CANCER Res. 2007; 13: 5109-5114.[Crossref]
• 28. Verhagen A.M., Coulson E.J., Vaux D.L.: Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biology 2001; 2: 3009.1-3009.10.[Crossref]
• 29. Wright C.W., Duckett C.S.: Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP. J Clin Invest 2005; 115: 2673-2678.[Crossref]
• 30. Yamamoto K. et al.: Expression of IAP proteins in myelodysplastic syndromes trans forming to overt leukemia. Leukemia Research 2004; 28: 1203-1211.[Crossref]
• 31. Yang L.Y., Li X.M.: The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Research 2000; 10: 169-177.[Crossref]
• 32. Hao Y., Sekine K., Kawabata A., Nakamura H., Ishoika T., Ohata H., KatayamaR., Hashimoto C., Zhang X., Tsuro T., Kwaito M. Apollon ubiquitinates Smac and caspases-9 and has an essential cytoprotetion function. Nature Cell Biol 2004; 6: abstract.[Crossref]
• 33. Sekine K., Hao Y., Suzuki Y., Takahashi R., Tsuruo T., Natio M. HtrA2 cleaves Apollon and induces cell death by IAP-binding motif in Apollon-deficient cells. Biochem Biophys Res Commun. 2005; 330: abstract
• 34. Hauser H.P., Bardoff M., Pyrowolakis G., Jentsch S. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J Cell Biol. 1998;141: abstract.

Identifiers

DOI

10.1515/cipms-2015-0011